Nevirapine: Started a Phase III trial

The international trial will evaluate patients for 18-24 months, and will include only patients who are non-nucleoside reverse transcriptor inhibitor-naive with CD4 counts ? 200.

Patients will be randomized to treatment with 200 mg Nevirapine once daily for two weeks, then 200 mg twice daily in combination with open-label 150 mg 3TC given twice daily. ...